Ranbaxy Argues It Can't Monopolize Drugs It Never Sold
Ranbaxy Pharmaceuticals urged a Massachusetts federal judge in oral arguments Friday to reject antitrust claims that it manipulated the regulatory approval system, arguing that it didn't defraud the process and that...To view the full article, register now.
Already a subscriber? Click here to view full article